Ownership and insider activity for Dianthus Therapeutics, Inc. (DNTH): recent transactions by executives and directors. Track how corporate insiders are trading the stock.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production,...
Price
| Price | $85.81 (closing price, November 4, 2026) |
| Market Cap | $4.8B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-17 | CARR EDWARD | M-Exempt | 20,000 | $358K |
| 2026-09-17 | CARR EDWARD | M-Exempt | 20,000 | $358K |
| 2026-09-17 | CARR EDWARD | S-Sale | 7,928 | $796K |
| 2026-09-17 | CARR EDWARD | S-Sale | 6,771 | $686K |
| 2026-09-17 | CARR EDWARD | S-Sale | 3,501 | $358K |
| 2026-09-17 | CARR EDWARD | S-Sale | 1,100 | $114K |
| 2026-09-17 | CARR EDWARD | S-Sale | 700 | $73K |
| 2026-09-01 | Randhawa Simrat | M-Exempt | 9,375 | $207K |
| 2026-09-01 | Randhawa Simrat | M-Exempt | 7,500 | $134K |
| 2026-09-01 | Randhawa Simrat | M-Exempt | 6,249 | $136K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.5M | $51.6M | $58.3M | $65.1M | $58.2M | $131.7M | $15.4M | $132.3M | $22.8M | $51.1M |
| Short-term Investments | 0 | 0 | $84.2M | $80.7M | $90.7M | $45.3M | $60.1M | $41.4M | $252.4M | $353.2M |
| Receivables | $6.2M | 0 | 0 | 0 | 0 | 0 | $5.6M | $478,000 | $807,000 | $102,000 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $10.8M | $52.5M | $145.3M | $149.8M | $151.5M | $180.7M | $82.0M | $177.5M | $280.9M | $409.4M |
| Property, Plant & Equipment | $508,000 | $1.7M | $3.1M | $9.9M | $8.3M | $7.5M | $956,000 | $800,000 | $1.7M | $1.6M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $11.3M | $54.5M | $157.3M | $161.5M | $161.6M | $189.9M | $83.1M | $179.4M | $374.0M | $530.9M |
| Accounts Payable | $1.7M | $167,000 | $3.5M | $2.8M | $3.8M | $3.0M | $1.2M | $2.6M | $4.6M | $9.7M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $2.3M | $4.1M | $10.4M | $14.1M | $11.4M | $10.9M | $8.2M | $9.6M | $18.5M | $30.7M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $1.0M |
| Total Liabilities | $2.3M | $4.1M | $11.7M | $20.3M | $17.7M | $17.3M | $9.5M | $10.5M | $21.5M | $37.5M |
| Retained Earnings | -$9.7M | -$45.2M | -$102.7M | -$179.5M | -$254.4M | -$325.6M | -$45.9M | -$89.4M | -$174.4M | -$336.7M |
| Total Equity | $9.0M | $50.3M | $145.6M | $141.2M | $143.9M | $172.7M | $73.7M | $168.9M | $352.5M | $493.4M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 | $788,000 | $585,000 | $1.5M | $1.4M |
| Net Debt | -$4.5M | -$51.6M | -$142.6M | -$145.7M | -$148.8M | -$176.9M | -$74.7M | -$173.1M | -$273.8M | -$402.9M |
| Working Capital | $8.5M | $48.4M | $134.9M | $135.7M | $140.1M | $169.8M | $73.8M | $167.8M | $262.5M | $378.7M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 30.02 |
| Piotroski F-Score | 1 |
| Altman Z-Score | 23.77 |
Profitability
| Return on Equity | -3.87% |
| Return on Invested Capital | -18.91% |
| Return on Assets | -3.12% |
| Gross Margin | 94.96% |
| Operating Margin | -15,651.72% |
| Net Margin | -2,638.40% |
Related companies: IMVT · VERA · VRTX · 0QZU.L · MRNA · REGN · 0R2M.L · ARGX
Explore sector: Healthcare · Biotechnology
More sections of DNTH: Overview · Financials · Valuation · Estimates · Technical
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks